<p>根据最近向证券交易委员会的披露，Bellevue Group AG 在第二季度将其在 PROCEPT BioRobotics Corporation（纳斯达克代码：PRCT - 免费报告）的股份增加了 17.9%。该机构投资者在季度内购买了 74,355 股后，持有该公司 489,278 股股票。截至其最近向证券交易委员会的备案，Bellevue Group AG 持有 PROCEPT BioRobotics 的股份占比为 0.88%，价值 28,182,000 美元。</p>
<p>获取 <strong>PROCEPT BioRobotics</strong> 警报：</p>
<ul>
<li>3 只被低估的机器人股票有望获得巨大收益</li>
</ul>
<p>其他一些对冲基金也调整了对该股票的持有。三菱 UFJ 信托银行在第二季度新建了对 PROCEPT BioRobotics 的持仓，价值 5,892,000 美元。Lisanti Capital Growth LLC 在第二季度新购入了价值 2,532,000 美元的 PROCEPT BioRobotics 股份。Osterweis Capital Management Inc.在第一季度将其在 PROCEPT BioRobotics 的持股增加了 98.0%。Osterweis Capital Management Inc.现在持有 173,735 股该公司股票，价值 10,122,000 美元，此前在上个季度又购买了 85,990 股。三菱 UFJ 资产管理有限公司在第二季度将其在 PROCEPT BioRobotics 的持股增加了 109.3%。三菱 UFJ 资产管理有限公司现在持有 159,874 股该公司股票，价值 9,209,000 美元，此前在上个季度又购买了 83,498 股。最后，Candriam S.C.A.在第二季度将其在 PROCEPT BioRobotics 的持仓增加了 104.8%。Candriam S.C.A.现在持有 63,125 股该公司股票，价值 3,636,000 美元，此前在上个季度又购买了 32,301 股。89.46% 的股票由机构投资者和对冲基金持有。</p>
<h2>PROCEPT BioRobotics 价格表现</h2>
<p>PRCT 周五开盘价为 35.99 美元。该公司的债务与股本比率为 0.14，流动比率为 8.44，速动比率为 7.20。该股票的市值为 20.1 亿美元，市盈率为-23.52，贝塔值为 0.99。该公司的 50 日简单移动平均线为 33.01 美元，200 日简单移动平均线为 43.59 美元。PROCEPT BioRobotics Corporation 的年低为 27.80 美元，年高为 92.92 美元。</p>
<ul>
<li>PROCEPT BioRobotics 是外科机器人领域的下一个大事件吗？</li>
</ul>
<p>PROCEPT BioRobotics（纳斯达克代码：PRCT - 获取免费报告）最近在 11 月 4 日发布了季度财报。该公司报告每股收益为（0.38 美元），超出市场共识预期的（0.41 美元）0.03 美元。该公司在本季度的收入为 8333 万美元，而分析师预期为 8078 万美元。PROCEPT BioRobotics 的净利润率为-28.20%，股本回报率为-21.72%。PROCEPT BioRobotics 的收入同比增长 42.6%。在去年同期，该公司每股收益为（0.40 美元）。卖方分析师预计 PROCEPT BioRobotics Corporation 在当前财政年度将发布-1.75 的每股收益。</p>
<h2>分析师设定新目标价</h2>
<p>PRCT 近期成为多份分析师报告的主题。Piper Sandler 在 11 月 5 日的研究报告中重申了 “增持” 评级，并将 PROCEPT BioRobotics 的目标价下调至 50.00 美元（之前为 55.00 美元）。美国银行在 12 月 8 日的研究报告中重申了 “中性” 评级，并将 PROCEPT BioRobotics 的目标价下调至 38.00 美元（之前为 55.00 美元）。Jefferies Financial Group 在周五将 PROCEPT BioRobotics 的评级上调至 “买入”。Leerink Partners 在 11 月 5 日的报告中重申了 “跑赢大盘” 评级，并将 PROCEPT BioRobotics 的目标价设定为 55.00 美元。最后，富国银行将 PROCEPT BioRobotics 的目标价从 58.00 美元下调至 51.00 美元，并在 11 月 5 日的研究报告中对该公司给予 “增持” 评级。十位投资分析师对该股票给予了买入评级，两位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，该公司的共识评级为 “适度买入”，平均目标价为 53.70 美元。</p>
<ul>
<li>为什么 Intuitive Surgical 股票在医疗行业中占据主导地位</li>
</ul>
<p><strong>阅读我们对 PRCT 的最新股票分析</strong></p>
<h2>PROCEPT BioRobotics 公司简介</h2>
<p>（免费报告）</p>
<p>PROCEPT BioRobotics Corporation 是一家外科机器人公司，专注于在美国和国际上开发变革性泌尿学解决方案。该公司开发、制造和销售 AquaBeam 机器人系统，这是一种图像引导的外科机器人系统，旨在用于微创泌尿外科手术，重点治疗良性前列腺增生（BPH）。</p>
<h2>另见</h2>
<ul>
<li>五只我们更看好的股票，胜过 PROCEPT BioRobotics</li>
<li>加拿大债券市场假期：如何投资和交易</li>
<li>Synopsys 因 Ansys 整合推动增长而出现看涨转变</li>
<li>万亿美元市值的意义超越数字本身</li>
<li>你能给自己最好的节日礼物是什么？Costco 股票</li>
<li>罗素 2000 指数，投资者如何利用它进行盈利交易</li>
<li>为什么 Zscaler 股票在 30% 的抛售后可能准备反弹</li>
</ul>
<p><strong>想看看其他对冲基金持有 PRCT 的情况吗？</strong> 访问 HoldingsChannel.com 以获取 PROCEPT BioRobotics Corporation（纳斯达克代码：PRCT - 免费报告）的最新 13F 备案和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFJDVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFJDVA"/></p>
<p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在 PROCEPT BioRobotics 吗？</h2>
<p>在考虑 PROCEPT BioRobotics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 PROCEPT BioRobotics 并不在名单上。</p>
<p>虽然 PROCEPT BioRobotics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

PRCT

<p>贝尔维尤集团（Bellevue Group AG）在第二季度将其在 PROCEPT BioRobotics 的持股比例增加了 17.9%，增持了 74,355 股，目前持有该公司 0.88% 的股份。该股票的估值为 2818 万美元。其他投资者也调整了他们的持股。PROCEPT BioRobotics 报告第三季度收入同比增长 42.6%，净利润率为负 28.20%。分析师设定的共识目标价为 53.70 美元，评级为 “适度买入”</p>

<p>Bellevue Group AG raised its stake in shares of PROCEPT BioRobotics Corporation (NASDAQ:PRCT - Free Report) by 17.9% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 489,278 shares of the company's stock after purchasing an additional 74,355 shares during the quarter. Bellevue Group AG owned 0.88% of PROCEPT BioRobotics worth $28,182,000 as of its most recent filing with the Securities and Exchange Commission.</p>
<div class="lb-trans"><p>根据最近向证券交易委员会的披露，Bellevue Group AG 在第二季度将其在 PROCEPT BioRobotics Corporation（纳斯达克代码：PRCT - 免费报告）的股份增加了 17.9%。该机构投资者在季度内购买了 74,355 股后，持有该公司 489,278 股股票。截至其最近向证券交易委员会的备案，Bellevue Group AG 持有 PROCEPT BioRobotics 的股份占比为 0.88%，价值 28,182,000 美元。</p>
</div><p>Get <strong>PROCEPT BioRobotics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>PROCEPT BioRobotics</strong> 警报：</p>
</div><ul>
<li>3 Underrated Robotics Stocks Poised for Huge Gains</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只被低估的机器人股票有望获得巨大收益</li>
</ul>
</div><p>A number of other hedge funds have also modified their holdings of the stock. Mitsubishi UFJ Trust &amp; Banking Corp acquired a new position in PROCEPT BioRobotics during the second quarter worth $5,892,000. Lisanti Capital Growth LLC acquired a new stake in shares of PROCEPT BioRobotics in the 2nd quarter valued at $2,532,000. Osterweis Capital Management Inc. grew its holdings in shares of PROCEPT BioRobotics by 98.0% in the 1st quarter. Osterweis Capital Management Inc. now owns 173,735 shares of the company's stock worth $10,122,000 after purchasing an additional 85,990 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in shares of PROCEPT BioRobotics by 109.3% in the 2nd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 159,874 shares of the company's stock worth $9,209,000 after purchasing an additional 83,498 shares during the last quarter. Finally, Candriam S.C.A. increased its position in shares of PROCEPT BioRobotics by 104.8% during the 2nd quarter. Candriam S.C.A. now owns 63,125 shares of the company's stock worth $3,636,000 after purchasing an additional 32,301 shares in the last quarter. 89.46% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他一些对冲基金也调整了对该股票的持有。三菱 UFJ 信托银行在第二季度新建了对 PROCEPT BioRobotics 的持仓，价值 5,892,000 美元。Lisanti Capital Growth LLC 在第二季度新购入了价值 2,532,000 美元的 PROCEPT BioRobotics 股份。Osterweis Capital Management Inc.在第一季度将其在 PROCEPT BioRobotics 的持股增加了 98.0%。Osterweis Capital Management Inc.现在持有 173,735 股该公司股票，价值 10,122,000 美元，此前在上个季度又购买了 85,990 股。三菱 UFJ 资产管理有限公司在第二季度将其在 PROCEPT BioRobotics 的持股增加了 109.3%。三菱 UFJ 资产管理有限公司现在持有 159,874 股该公司股票，价值 9,209,000 美元，此前在上个季度又购买了 83,498 股。最后，Candriam S.C.A.在第二季度将其在 PROCEPT BioRobotics 的持仓增加了 104.8%。Candriam S.C.A.现在持有 63,125 股该公司股票，价值 3,636,000 美元，此前在上个季度又购买了 32,301 股。89.46% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>PROCEPT BioRobotics Price Performance</h2>
<div class="lb-trans"><h2>PROCEPT BioRobotics 价格表现</h2>
</div><p>PRCT opened at $35.99 on Friday. The company has a debt-to-equity ratio of 0.14, a current ratio of 8.44 and a quick ratio of 7.20. The stock has a market capitalization of $2.01 billion, a P/E ratio of -23.52 and a beta of 0.99. The company's 50 day simple moving average is $33.01 and its 200-day simple moving average is $43.59. PROCEPT BioRobotics Corporation has a one year low of $27.80 and a one year high of $92.92.</p>
<div class="lb-trans"><p>PRCT 周五开盘价为 35.99 美元。该公司的债务与股本比率为 0.14，流动比率为 8.44，速动比率为 7.20。该股票的市值为 20.1 亿美元，市盈率为-23.52，贝塔值为 0.99。该公司的 50 日简单移动平均线为 33.01 美元，200 日简单移动平均线为 43.59 美元。PROCEPT BioRobotics Corporation 的年低为 27.80 美元，年高为 92.92 美元。</p>
</div><ul>
<li>Is PROCEPT BioRobotics the Next Big Thing in Surgical Robotics?</li>
</ul>
<div class="lb-trans"><ul>
<li>PROCEPT BioRobotics 是外科机器人领域的下一个大事件吗？</li>
</ul>
</div><p>PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last posted its quarterly earnings data on Tuesday, November 4th. The company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.03. The firm had revenue of $83.33 million during the quarter, compared to analysts' expectations of $80.78 million. PROCEPT BioRobotics had a negative net margin of 28.20% and a negative return on equity of 21.72%. PROCEPT BioRobotics's revenue was up 42.6% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.40) EPS. Sell-side analysts anticipate that PROCEPT BioRobotics Corporation will post -1.75 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>PROCEPT BioRobotics（纳斯达克代码：PRCT - 获取免费报告）最近在 11 月 4 日发布了季度财报。该公司报告每股收益为（0.38 美元），超出市场共识预期的（0.41 美元）0.03 美元。该公司在本季度的收入为 8333 万美元，而分析师预期为 8078 万美元。PROCEPT BioRobotics 的净利润率为-28.20%，股本回报率为-21.72%。PROCEPT BioRobotics 的收入同比增长 42.6%。在去年同期，该公司每股收益为（0.40 美元）。卖方分析师预计 PROCEPT BioRobotics Corporation 在当前财政年度将发布-1.75 的每股收益。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>PRCT has been the topic of a number of recent analyst reports. Piper Sandler restated an &#34;overweight&#34; rating and issued a $50.00 price target (down from $55.00) on shares of PROCEPT BioRobotics in a research report on Wednesday, November 5th. Bank of America reiterated a &#34;neutral&#34; rating and issued a $38.00 target price (down previously from $55.00) on shares of PROCEPT BioRobotics in a research note on Monday, December 8th. Jefferies Financial Group raised PROCEPT BioRobotics to a &#34;buy&#34; rating in a report on Friday. Leerink Partners reaffirmed an &#34;outperform&#34; rating and set a $55.00 price target on shares of PROCEPT BioRobotics in a report on Wednesday, November 5th. Finally, Wells Fargo &amp; Company cut their price objective on PROCEPT BioRobotics from $58.00 to $51.00 and set an &#34;overweight&#34; rating for the company in a research report on Wednesday, November 5th. Ten investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $53.70.</p>
<div class="lb-trans"><p>PRCT 近期成为多份分析师报告的主题。Piper Sandler 在 11 月 5 日的研究报告中重申了 “增持” 评级，并将 PROCEPT BioRobotics 的目标价下调至 50.00 美元（之前为 55.00 美元）。美国银行在 12 月 8 日的研究报告中重申了 “中性” 评级，并将 PROCEPT BioRobotics 的目标价下调至 38.00 美元（之前为 55.00 美元）。Jefferies Financial Group 在周五将 PROCEPT BioRobotics 的评级上调至 “买入”。Leerink Partners 在 11 月 5 日的报告中重申了 “跑赢大盘” 评级，并将 PROCEPT BioRobotics 的目标价设定为 55.00 美元。最后，富国银行将 PROCEPT BioRobotics 的目标价从 58.00 美元下调至 51.00 美元，并在 11 月 5 日的研究报告中对该公司给予 “增持” 评级。十位投资分析师对该股票给予了买入评级，两位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，该公司的共识评级为 “适度买入”，平均目标价为 53.70 美元。</p>
</div><ul>
<li>Why Intuitive Surgical Stock is Dominating the Medical Sector</li>
</ul>
<div class="lb-trans"><ul>
<li>为什么 Intuitive Surgical 股票在医疗行业中占据主导地位</li>
</ul>
</div><p><strong>Read Our Latest Stock Analysis on PRCT</strong></p>
<div class="lb-trans"><p><strong>阅读我们对 PRCT 的最新股票分析</strong></p>
</div><h2>PROCEPT BioRobotics Profile</h2>
<div class="lb-trans"><h2>PROCEPT BioRobotics 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).</p>
<div class="lb-trans"><p>PROCEPT BioRobotics Corporation 是一家外科机器人公司，专注于在美国和国际上开发变革性泌尿学解决方案。该公司开发、制造和销售 AquaBeam 机器人系统，这是一种图像引导的外科机器人系统，旨在用于微创泌尿外科手术，重点治疗良性前列腺增生（BPH）。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than PROCEPT BioRobotics</li>
<li>Canada Bond Market Holiday: How to Invest and Trade</li>
<li>Synopsys Sees Bullish Shift as Ansys Integration Drives Growth</li>
<li>The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number</li>
<li>The Best Holiday Present You Can Give Yourself? Costco Stock</li>
<li>Russell 2000 Index, How Investors Use it For Profitable Trading</li>
<li>Why Zscaler Stock Could Be Ready to Bounce After a 30% Selloff</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 PROCEPT BioRobotics</li>
<li>加拿大债券市场假期：如何投资和交易</li>
<li>Synopsys 因 Ansys 整合推动增长而出现看涨转变</li>
<li>万亿美元市值的意义超越数字本身</li>
<li>你能给自己最好的节日礼物是什么？Costco 股票</li>
<li>罗素 2000 指数，投资者如何利用它进行盈利交易</li>
<li>为什么 Zscaler 股票在 30% 的抛售后可能准备反弹</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding PRCT?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PROCEPT BioRobotics Corporation (NASDAQ:PRCT - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对冲基金持有 PRCT 的情况吗？</strong> 访问 HoldingsChannel.com 以获取 PROCEPT BioRobotics Corporation（纳斯达克代码：PRCT - 免费报告）的最新 13F 备案和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFJDVA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=PRCT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in PROCEPT BioRobotics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 PROCEPT BioRobotics 吗？</h2>
</div><p>Before you consider PROCEPT BioRobotics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 PROCEPT BioRobotics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PROCEPT BioRobotics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 PROCEPT BioRobotics 并不在名单上。</p>
</div><p>While PROCEPT BioRobotics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 PROCEPT BioRobotics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Bellevue Group AG 收购了 74,355 股 PROCEPT BioRobotics Corporation 的股票 $PRCT